Literature DB >> 19281464

Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions.

Bashar Zelhof1, Martin Lowry, Greta Rodrigues, Sigurd Kraus, Lindsay Turnbull.   

Abstract

OBJECTIVE: To assess the use of a semiquantitative analysis of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) to produce indices for enhancement curves that might enable differentiation between malignant prostatic lesions and normal peripheral zone (PZ). PATIENTS AND METHODS: Fifty-two patients scheduled for radical prostatectomy underwent DCE-MRI before surgery using a 3 T scanner. The DCE images were used to generate variables from changes in signal intensity for pathologically confirmed malignant areas and the normal PZ, using whole-mounted pathology specimens as a reference to delineate regions of interest (ROI). These variables included maximum enhancement index (MaxEI), time to MaxEI at 30 s, the initial and final slopes of signal intensity change, and the area under curve. A threshold value for each DCE variable was identified, and the sensitivity and specificity were obtained.
RESULTS: Malignant lesions had a 56% higher MaxEI than normal PZ and took half the time to reach MaxEI (P<0.001). Hence, at 30 s, cancer lesions have double the mean (sd) EI than normal PZ, of 2.22 (1.04) vs 1.04 (0.51), respectively. Tumours showed significant washout of contrast medium, which was reflected in the final slope of the curve being negative, as opposed to positive for normal PZ. The combined data of DCE variables, using a logistic regression test, gave a mean (95% confidence interval) sensitivity and specificity of 89 (81-96)% and 90 (83-97)%, respectively.
CONCLUSION: This technique provides good discrimination of malignant lesions that might enable accurate localisation of the lesion. It is a simple, semiquantitive, noninvasive method that reflects the unusual vascular characteristics of newly formed microvessels and the changes in the interstitium that occur in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281464     DOI: 10.1111/j.1464-410X.2009.08457.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

1.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

Authors:  Jayant Narang; Rajan Jain; Ali Syed Arbab; Tom Mikkelsen; Lisa Scarpace; Mark L Rosenblum; David Hearshen; Abbas Babajani-Feremi
Journal:  Neuro Oncol       Date:  2011-07-29       Impact factor: 12.300

Review 2.  Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI.

Authors:  Xin Wang; Michael A Jacobs; Laura Fayad
Journal:  NMR Biomed       Date:  2011-07       Impact factor: 4.044

Review 3.  MRI for men undergoing active surveillance or with rising PSA and negative biopsies.

Authors:  Orit Raz; Masoom Haider; John Trachtenberg; Dan Leibovici; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

4.  Targeted focal therapy for prostate cancer: a review of the literature.

Authors:  Kathryn F Sullivan; E David Crawford
Journal:  Ther Adv Urol       Date:  2009-08

Review 5.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12

Review 6.  Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Authors:  John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany
Journal:  J Magn Reson Imaging       Date:  2013-05       Impact factor: 4.813

7.  Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint.

Authors:  Liang Li; Liang Wang; Zhaoyan Feng; Zhiquan Hu; Guoping Wang; Xianglin Yuan; He Wang; Daoyu Hu
Journal:  Quant Imaging Med Surg       Date:  2013-04

Review 8.  Perfusion MRI: the five most frequently asked clinical questions.

Authors:  Marco Essig; Thanh Binh Nguyen; Mark S Shiroishi; Marc Saake; James M Provenzale; David S Enterline; Nicoletta Anzalone; Arnd Dörfler; Àlex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

9.  The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI.

Authors:  Andriy Fedorov; Tobias Penzkofer; Michelle S Hirsch; Trevor A Flood; Mark G Vangel; Paul Masry; Clare M Tempany; Robert V Mulkern; Fiona M Fennessy
Journal:  Acad Radiol       Date:  2015-02-13       Impact factor: 3.173

10.  Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI.

Authors:  Nikolaos Dikaios; Jokha Alkalbani; Mohamed Abd-Alazeez; Harbir Singh Sidhu; Alex Kirkham; Hashim U Ahmed; Mark Emberton; Alex Freeman; Steve Halligan; Stuart Taylor; David Atkinson; Shonit Punwani
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.